Skip to Main Content

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Conditions

Alzheimer's Disease

Phase III

What is the purpose of this trial?

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.

  • Trial with
    Eli Lilly and Company
  • Start Date
    03/24/2021
  • End Date
    03/09/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/17/2021
  • Study HIC
    #2000028807